Skip to main content

Caribou Biosciences, Inc. (CRBU) Stock Forecast

Data as of Oct 31, 2026

Healthcare · Current price $0.42 (-5.04%)

Consensus Target
$5.00
Upside
+136.7%
Analysts
6
Rating
Hold(2.67)

Price Target Range

Low $3.00Consensus $5.00High $7.00
▲ Current $0.42

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Hold
Strong Buy0
Buy1
Hold4
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Nov 4, 2025Asthika GoonewardeneTruist Financial$7.00+1556.6%
Jun 3, 2024Liisa BaykoEvercore ISI$3.00+610.0%

CRBU vs Sector & Market

MetricCRBUHealthcare AvgLarge Cap Avg
Analyst Rating2.672.252.41
Analyst Count6819
Target Upside+136.7%+153002.0%+21.5%
P/E Ratio-1.333.4738.49

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$19M$19M$19M2
2027-12-31$6M$25M$43M4
2028-12-31$9M$27M$74M5
2029-12-31$23M$74M$199M2
2030-12-31$51M$164M$444M2

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.22$-0.22$-0.221
2027-12-31$-1.35$-1.30$-1.243
2028-12-31$-1.91$-1.51$-1.155
2029-12-31$-5.57$-1.74$-0.191
2030-12-31$-5.89$-1.84$-0.201

Frequently Asked Questions

What is the analyst consensus for CRBU?

The consensus among 6 analysts covering Caribou Biosciences, Inc. (CRBU) is Hold with an average price target of $5.00.

What is the highest price target for CRBU?

The highest price target for CRBU is $7.00, set by Asthika Goonewardene at Truist Financial on 2025-11-04.

What is the lowest price target for CRBU?

The lowest price target for CRBU is $3.00, set by Liisa Bayko at Evercore ISI on 2024-06-03.

How many analysts cover CRBU?

6 analysts have issued ratings for Caribou Biosciences, Inc. in the past 12 months.

Is CRBU a buy or sell right now?

Based on 6 analyst ratings, CRBU has a consensus rating of Hold (2.67/5) with a +136.7% upside to the consensus target of $5.00.

What are the earnings estimates for CRBU?

Analysts estimate CRBU will report EPS of $-0.22 for the period ending 2026-12-31, with revenue estimated at $19M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.